Introduction {#sec1_1}
============

Vemurafenib is a BRAF inhibitor widely used as a targeted therapy in BRAF-mutated metastatic melanoma \[[@B1]\]. BRAF mutations are present in 40--60% of patients with cutaneous melanoma \[[@B1], [@B2]\], by far the most common mutation being V600E \[[@B1], [@B2], [@B3]\].

Vemurafenib therapy is associated with several cutaneous side effects, including palmoplantar erythema, UVA-induced photosensitivity, hyperkeratotic lesions of the soles, development of keratoacanthomas and squamous cell carcinomas as well as new primary melanomas \[[@B1], [@B2], [@B3], [@B4], [@B5]\]. Inflammatory cutaneous side effects were reported as early as 3--6 weeks after initiation of vemurafenib treatment. So far only a few reports describing radiosensitization or radiation recall dermatitis following treatment with BRAF inhibitors exist \[[@B6]\].

We report the development of localized epidermal cysts following radiotherapy and treatment with vemurafenib.

Case Report {#sec1_2}
===========

A 43-year-old female patient with a recently diagnosed metastatic melanoma, AJCC stage IV, was referred for evaluation of cystic lesions on the lateral face and left neck region. These cysts had started growing during the previous 6 weeks. The patient initially presented with an 8 × 15 cm exophytic pigmented tumor mass in the left inframandibular neck region. Light microscopy studies confirmed the diagnosis of melanoma, although it remained unclear whether the lesion represented a primary or a local metastasis. Staging exams including total body computed tomography showed a pelvic tumor mass 20 cm in diameter with diffuse enlargement of mesenteric, paraaortic and cervical lymph nodes. The lesions were regarded as lymph node metastases of the melanoma. Magnetic resonance imaging of the brain excluded the presence of brain metastases.

Because of the advanced stage of the tumor palliative, neoadjuvant, hypofractionated radiotherapy was started. The exophytic tumor in the neck was given a total radiation dose of 30 Gy with 6 × 5 Gy per daily fraction administered 5 days per week. Based on the detection of a BRAF mutation V600E in exon 15, the patient was given vemurafenib (Zelboraf^®^) 960 mg twice daily 3 days after completion of the radiotherapy. At the follow-up visit 3 months after radiotherapy, the patient was found to have multiple epidermal cysts in the previous irradiation field, i.e. the left temple, ear and auditory canal and posterior neck region (fig. [1](#F1){ref-type="fig"}). Light microscopy studies confirmed the diagnosis (fig. [2](#F2){ref-type="fig"}). At the 1-year follow-up visit the patient\'s situation was stable and the number of epidermal cysts unchanged.

Discussion {#sec1_3}
==========

The use of BRAF inhibitors is associated with numerous cutaneous side effects. Most notably, BRAF inhibition leads to the formation of squamous cell carcinomas in RAS-primed cells due to an activation of the MAPK pathway \[[@B3], [@B7]\]. Nevertheless, there are few data about the side effects related to the combined use of BRAF inhibitors and radiotherapy.

In our case, the development of cysts limited to a previously irradiated field was highly unusual and peculiar in our experience. Even though milia-like epidermal cysts have been described in patients treated with the BRAF inhibitor vemurafenib \[[@B8]\], in our case this phenomenon was specifically observed only in the irradiated field, suggesting that the irradiation resulted in a localized susceptibility for the side effects of vemurafenib in the context of a so-called radiosensitization or radiation recall dermatitis. Nevertheless the exact pathomechanisms responsible for a radiation recall dermatitis remain unclear. The irradiation is likely to lead to an inflammatory reaction and tissue damage related to the release of inflammatory cytokines such as TNF-α, interleukin-1 and interleukin-6 \[[@B9]\]. Initiation of medicamentous therapy may again trigger a local reaction by releasing these cytokines \[[@B9]\].

Previous in vitro studies have shown that simultaneous administration of radiotherapy and sorafenib is associated with enhanced cytotoxic effects. It is conceivable that the latter is related to radiation-induced DNA damage with a higher cell count in a vulnerable phase of the cell cycle together with an additional inhibition of DNA repair by sorafenib \[[@B10]\]. Another in vitro model provided evidence that BRAF-positive melanoma cells are radiosensitized following BRAF inhibition \[[@B11]\]. In our case, the formation of cystic lesions may be dependent on RAS activation \[[@B3]\], as reported for keratoacanthomas and squamous cell carcinoma.

Only a few similar cases of localized skin reactions in irradiated areas following BRAF inhibition have been described so far. In one other case report cystic lesions were observed \[[@B12]\]. Boussemart et al. \[[@B8], [@B13]\] reported two cases of pruriginous skin reactions. Ducassou et al. \[[@B9]\] and Satzger et al. \[[@B6]\] reported cases of an asymptomatic erythematous reaction limited to the irradiated area, an observation suggesting a cutaneous radiosensitization related to vemurafenib. Also some cases of severe radiotherapy-induced visceral toxicity were observed \[[@B14], [@B15]\].

Recently, an increasing number of both cutaneous and visceral radiation recall reactions have been reported following the administration of BRAF inhibitors. Since little is known about the pathogenesis of these side effect conditions, further research in the growing field of combined kinase inhibitor treatment with or without radiation has to be undertaken.
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